December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0038 -0.0030 (-44.12%)
Streaming Delayed Price Updated: 11:56 AM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
Lexaria's Submits Investigational New Drug Application
Via ACCESSWIRE
News headline image
Lexaria Releases Annual Letter from the CEO
Via ACCESSWIRE
News headline image
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
Via ACCESSWIRE
News headline image
Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science
Via ACCESSWIRE
News headline image
Lexaria Receives New Patents
Via ACCESSWIRE
News headline image
Lexaria Appoints New Chief Financial Officer
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's Investigational New Drug Application Filing Update
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
Via ACCESSWIRE
News headline image
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Granted Two New Patents in Canada
Via ACCESSWIRE
News headline image
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Via ACCESSWIRE
News headline image
Lexaria Provides Update on Investigational New Drug Application Progress
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Results from Human Oral Nicotine Study Evaluating DehydraTECH(TM)-Nicotine
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Designing Human Clinical Study of DehydraTECH-CBD for Weight Loss, Diabetes Control
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
Via ACCESSWIRE
News headline image
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
Via ACCESSWIRE
News headline image
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
Via ACCESSWIRE
News headline image
Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
Via ACCESSWIRE
News headline image
Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases ↗
 
Via Benzinga
News headline image
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.